CASSAVA SCIENCES SAVA 深 沪
已收盘 08-29 16:00:00 美东时间
2.28
-0.100
-4.20%
华盛通- 最 高2.39
- 今 开2.38
- 成交量 38.64万股
- 最 低 2.28
- 昨 收 2.38
- 总市值 1.10亿
- 52周最高 33.98
- 市盈率 静 --
- 换手率 0.80%
- 52周最低 1.15
- 委 比 -38.08%
- 总股本 4830.79万
- 历史最高 146.16
- 量 比 0.67
- 振 幅 4.62%
- 历史最低 1.00
- 每 手 1
- 风险率 10.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Cassava Sciences, Inc. announced that its CEO, Rick Barry, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8, 2025. The event will feature a corporate presentation at 5 PM ET, available via webcast and replay on Cassava's investor website for 90 days. Cassava, a biotechnology company focused on CNS disorder treatments, is based in Austin, Texas.
08-25 12:00
Cassava Sciences Advances Simufilam for Epilepsy Treatment
Cassava Sciences ( ($SAVA) ) has released its Q2 earnings. Here is a breakdown ...
08-19 11:53
Cassava Sciences GAAP EPS of -$0.92
Cassava Sciences press release (NASDAQ:SAVA): Q2 GAAP EPS of -$0.92. Cash and cash equivalents were $112.4 million, with no debt, as of June 30, 2025. This compares to cash and cash equivalents of $12...
08-14 19:41
Cassava Sciences Q2 EPS $(0.92) Down From $0.13 YoY
Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.92) per share. This is a 807.69 percent decrease over earnings of $0.13 per share from the same period last year.
08-14 19:35
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Cassava Sciences reported Q2 2025 results, including a net loss of $44.2 million, cash of $112.4 million, and plans to advance simufilam for TSC-related epilepsy. The company appointed new neuroscience leaders and settled securities litigation with a $31.25 million loss contingency.
08-14 11:30
Ginkgo Bioworks files $500M mixed securities shelf
Ginkgo Bioworks (NYSE:DNA) filed a prospectus for the offer and sale of $500M mixed securities shelf. This preliminary prospectus is not an offer to sell these securities. Filing More on Ginkgo Bi...
08-08 05:59
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as Chief Medical Officer. With over 25 years of experience in developing therapies for epilepsy and other neurological disorders, Dr. Hulihan will focus on advancing simufilam, a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy. The clinical study for simufilam is expected to begin in H1 2026. Dr. Hulihan previously served as CMO at Marinus Pharmaceuticals and held s...
08-07 11:30
Cassava Sciences Reports Preclinical Results Of A Study Evaluating Simufilam In A Well-accepted Mouse Model Of Tuberous Sclerosis Complex (TSC)-related Epilepsy, First Clinical Study For Simufilam In TSC-related Epilepsy Expected To Begin In H1 2026
The Tsc1-CKO mice were treated with several doses of simufilam. Seizure activity was monitored for approximately three weeks after onset, and simufilam was evaluated against treatment with vehicle alone. The
08-04 19:33
SELLAS gains as mid-stage trial for leukemia drug succeeds
SELLAS Life Sciences (NASDAQ:SLS) traded higher in the premarket on Tuesday after the New York-based biotech said that a Phase 2 trial that tested its antitumor agent SLS009 (tambiciclib) as part of a...
07-15 20:22
